ANTICIPATE – Understanding the influence of psychosocial factors on treatment side effects and outcomes in patients with soft tissue sarcoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032748

Enrollment

100

Registered

2023-11-20

Start date

2024-06-10

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C49.0

Interventions

Group 1: Patients with soft tissue sarcoma and implementation of multimodal therapy (neoadjuvant/ adjuvant chemotherapy + regional hyperthermia, surgery, if applicable radiotherapy) are asked to compl

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Presence of a histologically confirmed soft tissue sarcoma in advanced stage (C.49.0) - Implementation of multimodal therapy starting with a neoadjuvant or adjuvant thermochemotherapy

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
- Toxicity according to CTCAE V.5/6 (assessment during the entire thermochemotherapy, laboratory controls at least once a week in the interval) - Radiologic response to therapy according to RECIST 1.1 (after the 2nd cycle, after the 4th cycle)	—

Secondary

Measure	Time frame
- B-IPQ (start of thermochemotherapy) - GEEE (start of thermochemotherapy, after the 1st cycle, after the 4th cycle and 1st aftercare presentation after completion of therapy) - QLQ-C30 (start of thermochemotherapy, after the 1st cycle, after the 4th cycle and 1st aftercare presentation after completion of therapy) - Pathological response to therapy according to EORTC-STBSG (resection usually after 4 cycles) - Progression-free survival (PFS, follow-up: 2 years) - Overall survival (OS, follow-up: 2 years)	—

Measure

Time frame

- B-IPQ (start of thermochemotherapy) - GEEE (start of thermochemotherapy, after the 1st cycle, after the 4th cycle and 1st aftercare presentation after completion of therapy) - QLQ-C30 (start of thermochemotherapy, after the 1st cycle, after the 4th cycle and 1st aftercare presentation after completion of therapy) - Pathological response to therapy according to EORTC-STBSG (resection usually after 4 cycles) - Progression-free survival (PFS, follow-up: 2 years) - Overall survival (OS, follow-up: 2 years)

—

Countries

Germany

Contacts

Public ContactAnton Burkhard-Meier

Medizinische Klinik und Poliklinik III der LMU München

anton.burkhardmeier@med.uni-muenchen.de+4989440074246

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026